The landscape of pharmacological obesity treatment has undergone a fundamental transformation in recent years, and adults navigating treatment options — along with their clinicians — now face a genuinely complex menu of choices. A definitive ranking of these agents, grounded in the full breadth of randomized evidence, has been missing until now.
This BMJ network meta-analysis synthesizes 262 randomized controlled trials enrolling nearly 100,000 participants and evaluating 19 distinct drugs against 24 clinical outcomes. At the one-year mark, tirzepatide (a dual GIP/GLP-1 receptor agonist) and the investigational combination cagrilintide-semaglutide emerged as the top performers, each producing roughly 14.8–14.9% mean body weight reduction versus lifestyle modification alone — effect sizes supported by moderate-to-high certainty GRADE evidence. Oral semaglutide delivered approximately 10.9% reduction, outperforming subcutaneous semaglutide's 9.8%, a counterintuitive finding given assumed bioavailability differences. The novel non-peptide oral GLP-1 agonist orforglipron achieved 9.9% reduction. Three pipeline agents — ecnoglutide, mazdutide, and retatrutide — showed 13.1–14.6% reductions, though rated very low to low certainty given limited trial data.
Placing this in broader context, prior pairwise meta-analyses could not simultaneously rank agents or estimate dose-response relationships across the full drug class. The frequentist random-effects and Bayesian dose-response modeling approach used here addresses that gap meaningfully. Several important caveats deserve attention: follow-up periods ranged from 12 to 172 weeks, creating heterogeneous comparison windows; most trials enrolled populations without severe comorbidities, limiting generalizability; and harms data — particularly long-term cardiovascular, gastrointestinal, and psychiatric signals — remain incompletely characterized for newer agents. The omission of head-to-head trials for several pipeline drugs means rankings carry real uncertainty. Overall, this analysis is among the most comprehensive produced to date and should shift how formulary decisions and clinical hierarchies are structured — though it does not resolve the durability question: what happens to weight after drug discontinuation remains a critical unanswered issue for all agents.